Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.58 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | BRAF | P15056 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3219815 | 0.85 | CXCR2 (0.67) | NPC1RAB9ACXCR2HTTSMN1; SMN2 | |
| SCHEMBL3221465 | 0.84 | NPC1 (0.65) | NPC1RAB9ACXCR2ALDH1A1HTT | |
| SCHEMBL3227232 | 0.82 | MAPT (0.63) | NPC1RAB9ACXCR2P2RX1GAA | |
| SCHEMBL3230547 | 0.81 | RECQL (0.62) | NPC1RAB9ACXCR2MAPTHTT | |
| SCHEMBL3225340 | 0.80 | CXCR2 (0.71) | NPC1RAB9ACXCR2ALDH1A1HPGD | |
| SCHEMBL3221810 | 0.80 | ADORA3 (0.63) | NPC1RAB9ACXCR2P2RX1ALDH1A1 | |
| SCHEMBL3225076 | 0.80 | CXCR2 (0.56) | NPC1RAB9ACXCR2MAPTHTT | |
| SCHEMBL3220123 | 0.79 | CXCR2 (0.55) | NPC1RAB9ACXCR2MAPTLMNA | |
| SCHEMBL5498009 | 0.79 | RAB9A (0.71) | NPC1RAB9AP2RX1ALDH1A1GAA | |
| SCHEMBL3220462 | 0.78 | ABL1 (0.55) | NPC1RAB9ACXCR2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100063105-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | UCB SA (GB) | 2010-03-11 | — | — | US | disclosed |
| US-7141590-B2 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | UCB SA (GB) | 2006-11-28 | — | — | US | disclosed |
| US-20050026965-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | DARWIN DISCOVERY LIMITED (GB) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063105-A1 | PHARMACEUTICAL USES AND SYNTHESIS OF NICOTINANILIDE-N-OXIDES | NNT, NAPRT, NNMT | NPC1 394/4885RAB9A 1926/4885CXCR2 1447/4885 |
| US-20050026965-A1 | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides | NNT, NAPRT, NNMT | NPC1 394/4885RAB9A 1926/4885CXCR2 1447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.